Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0K5BP
|
|||
| Former ID |
DIB014290
|
|||
| Drug Name |
HSP-990
|
|||
| Synonyms |
NVP-HSP990; 934343-74-5; HSP-990; UNII-E0WBA7B62L; HSP990 (NVP-HSP990); E0WBA7B62L; HSP990; NVP-HSP990(HSP990); SCHEMBL1351184; CHEMBL3360305; (7r)-2-Amino-7-[4-Fluoro-2-(6-Methoxypyridin-2-Yl)phenyl]-4-Methyl-7,8-Dihydropyrido[4,3-D]pyrimidin-5(6h)-One; NVP-HSP-990; HSP990 (NVP-HSP); NVP-HSP990,HSP990; DTXSID50239429; MolPort-023-219-119; 4u93; HSP990, NVP-HSP990; EX-A1560; AOB87737; NVP-HSP990 (HSP990); ZINC60329723; 2608AH; s7097; BDBM50031735; AKOS025404948; CS-3941; SB16642; BCP9001013
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [1] | |
| Company |
Novartis AG
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H18FN5O2
|
|||
| Canonical SMILES |
CC1=C2C(=NC(=N1)N)CC(NC2=O)C3=C(C=C(C=C3)F)C4=NC(=CC=C4)OC
|
|||
| InChI |
1S/C20H18FN5O2/c1-10-18-16(26-20(22)23-10)9-15(25-19(18)27)12-7-6-11(21)8-13(12)14-4-3-5-17(24-14)28-2/h3-8,15H,9H2,1-2H3,(H,25,27)(H2,22,23,26)/t15-/m1/s1
|
|||
| InChIKey |
WSMQUUGTQYPVPD-OAHLLOKOSA-N
|
|||
| CAS Number |
CAS 934343-74-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00879905) A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid Tumors. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.